Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

New research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).

Anti-TNF drugs have dramatically improved the lives of many patients living with rheumatoid arthritis. Not all patients respond to therapy however, with almost 40% showing a poor response to treatment.  

An alternative treatment to anti-TNF is the targeting of B-cells which are known to contribute to the development of RA by driving synovial inflammationThe B-cell depleting drug rituximab is used after an inadequate response to initial anti-TNF, but in this more therapy-resistant patient cohort, rituximab also shows limited improvement. The research team hypothesised that the number or markers of synovial tissue  B-cells before treatment could be used to predict a response.  

Peter Taylor, the Norman Collisson chair of musculoskeletal sciences at NDORMS said: We wanted to test the levels of B-cells in synovial tissue from patients with rheumatoid arthritis to see whether low or absent levels of the cells were preventing rituximab from working effectively. Against this we wanted to test whether tocilizumab, which works by inhibiting the action of IL-6, protein that can cause inflammation and damage, improved clinical outcomes. Our study was the first biopsy-driven randomised clinical trial in rheumatoid arthritis.” 

The study was a 48-week, biopsy-driven trial done in 19 centres across five European countries. Following a baseline synovial biopsy, patients were classified as B-cell poor or rich, then randomly assigned to receive either rituximab or tocilizumab infusions.  

To enhance the accuracy of the classification of B-cell poor and B-cell rich patients, baseline synovial biopsies from all participants were subjected to RNA sequencing and reclassified by B-cell molecular signature. At 16 weeks, any improvement in Clinical Disease Activity Index was measured in all patients.  

In the synovial biopsies classified as B-cell poor with RNA sequencing the tocilizumab group had a significantly higher response rate compared with the rituximab group.  

“Our trial represents a milestone towards precision rheumatology,” said Peter. “In future, binvestigating disease at the tissue level we can start to tailor our treatment and make the best drug selection for each individual patient’s needs. This may improve clinical response and have a major effect on related health and societal costs while reducing patient exposure to potentially toxic drugs. 

Similar stories

New approach to nail bed injury surgery could significantly cut NHS costs

According to a new Oxford study, changing clinical practice for finger injuries in children could save the NHS £720,000 per year.

Furniss Group paper wins journal award

Editors at the Journal of Hand Surgery have recognised the Furniss Group with an award for the best paper published in the Journal in 2022. The Editor’s Award recognises research with scientific importance, outstanding study stringency, and a high academic standard.

NIHR Fellowships awarded to NDORMS researchers

Congratulations to Eileen Morrow and Mae Chester-Jones who have received NIHR Doctoral Fellowships

ORUK Early Career Research Fellowship awarded to NDORMS researcher

Congratulations to Jack Tu who has been awarded an Orthopaedic Research UK Early Career Research Fellowship to explore the cause of knee pain after total knee replacement.

OCTRU - delivering answers to important clinical questions

The Oxford Clinical Trials Research Unit (OCTRU) has received NIHR benchmarking results and offers excellent value for money according to the report

Unhelpful thoughts about fracture symptoms hinder recovery

The importance of mindsets and feelings about fracture symptoms have been shown to be a key factor in recovery of musculoskeletal conditions.